TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Reviva Pharmaceuticals Holdings ( (RVPH) ) just unveiled an announcement.
On October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. announced it regained compliance with Nasdaq’s minimum Market Value of Listed Securities requirement, resolving a previous non-compliance issue. However, the company remains non-compliant with the Nasdaq’s minimum bid price requirement and has until November 10, 2025, to address this, considering options like a reverse stock split to meet the criteria.
The most recent analyst rating on (RVPH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.
Spark’s Take on RVPH Stock
According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.
Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.
To see Spark’s full report on RVPH stock, click here.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for the treatment of central nervous system, respiratory, and metabolic diseases.
Average Trading Volume: 7,921,582
Technical Sentiment Signal: Sell
Current Market Cap: $56.61M
For a thorough assessment of RVPH stock, go to TipRanks’ Stock Analysis page.